PFI-2 is an effective, specific and cell-active lysine methyltransferase SETD7 inhibitor (Ki/IC50: 0.33/2 nM), 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.
More Information Supplier Page
Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling. Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.
More Information Supplier Page
Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling. Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.
More Information Supplier Page 
Bioymifi is a novel and potent small-molecule activator of the TRAIL receptor DR5 in human cancer cells.
More Information Supplier Page
Ibudilast(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor. It is approved for use as an anti-inflammatory in Japan.
More Information Supplier Page
Bioymifi is a novel and potent small-molecule activator of the TRAIL receptor DR5 in human cancer cells.
More Information Supplier Page 
